CytoMed Therapeutics Ltd
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
42
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
stocks
Why it’s not all bad news for Flight Centre following downgrade
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,935.20 | 30.20 | -0.34% |
| CAC 40 | 8,431.61 | 46.12 | 0.55% |
| DAX 40 | 24,994.83 | 254.47 | 1.03% |
| Dow JONES (US) | 51,920.62 | 71.72 | 0.14% |
| FTSE 100 | 10,529.89 | 68.26 | 0.65% |
| HKSE | 22,548.27 | 528.64 | -2.29% |
| NASDAQ | 25,358.60 | 118.03 | -0.46% |
| Nikkei 225 | 69,602.72 | 2,763.63 | -3.82% |
| NZX 50 Index | 13,470.52 | 22.53 | -0.17% |
| S&P 500 | 7,357.49 | 0.73 | -0.01% |
| S&P/ASX 200 | 8,736.90 | 27.10 | -0.31% |
| SSE Composite Index | 4,021.02 | 99.26 | -2.41% |